Pasithea jumps on U.S. rollout of in-home therapy for mental health disorders

Pasithea Therapeutics

17/11/2021 13:58

** Shares of biotech co  KTTA.O  up ~9% at $2.74 pre-market
    ** Co starts offering in-home intravenous ketamine therapy
for patients suffering from treatment-resistant mental health
issues  urn:newsml:reuters.com:*:nGNX3MvzvD 
    ** Ketamine, initially approved as an anesthetic, has
recently also been used in lower doses to treat psychiatric
disorders
    ** "The treatment will be offered in New York City, Los
Angeles, San Diego, and San Francisco and will expand nationwide
in the coming months"- KTTA
    ** Co partnered with ZEN Healthcare to offer the therapy to
patients in the United Kingdom in October  urn:newsml:reuters.com:*:nGNX3h3KwF
    ** Up to Tuesday's close, stock had fallen 29.5% since its
Sept. 15 debut 

    

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))